The Efficacy of Sacubitril/Valsartan in the Treatment of Peripartum Cardiomyopathy: A Retrospective Analysis of Four Cases

Full abstract

Read the full abstract

Peripartum cardiomyopathy (PPCM) is a rare form of cardiomyopathy that develops in the last months of pregnancy or during the postpartum period and is characterized by a decrease in left ventricular ejection fraction below 45%. The diagnosis and management of PPCM can be difficult because the symptoms of the disease may be confused with normal pregnancy symptoms. This requires physicians to maintain a high level of clinical suspicion. PPCM can be fatal if not correctly diagnosed and treated. In this case series, we describe the clinical course of four PPCM patients treated with sacubitril/valsartan (S/V) in addition to standard therapy. In these patients, S/V therapy was associated with improvements in left ventricular function. By the end of the first month, all patients demonstrated recovery of ejection fraction above 50% and were classified as New York Heart Association (NYHA) class I. These preliminary observations suggest that S/V may represent a potential treatment option for PPCM, although confirmation in larger studies is required. Although data on the use of S/V in PPCM remain limited, our case series provides preliminary insights that warrant further investigation. PPCM can lead to permanent cardiac damage and other severe complications if not properly managed. The management of PPCM requires a multidisciplinary approach, emphasizing the importance of timely intervention. Our observations indicate that S/V could be considered a possible therapeutic option, but confirmation in larger cohorts is needed.